Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326272 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
A Phase 3 study of Psoriasis and Plaque Psoriasis, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 3
- Development phase
- 227
- Enrollment target
- 20
- Study locations
NCT02326272 is a Phase 3 study of Psoriasis and Plaque Psoriasis that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 227 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02326272, a Phase 3 study of Psoriasis and Plaque Psoriasis, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 227 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Certolizumab Pegol
Study Locations (20)
Ontario
- Ps0002 221 - Barrie
- Ps0002 223 - London
- Ps0002 222 - Peterborough
- Ps0002 220 - Richmond Hill
- Ps0002 224 - Waterloo
California
- Ps0002 214 - Bakersfield
- Ps0002 212 - Santa Monica
New York
- Ps0002 210 - New York
- Ps0002 206 - Rochester
Arizona
- Ps0002 203 - Phoenix
Florida
- Ps0002 204 - Ormond Beach
New Hampshire
- Ps0002 207 - Portsmouth
New Jersey
- Ps0002 202 - East Windsor
North Carolina
- Ps0002 209 - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2014-12-15 |
| Est. Completion | 2018-09-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02326272
The ClinicalTrials.gov registry entry for NCT02326272 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (53% lower). The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02326272 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ontario, California, New York.
Frequently Asked Questions
What is clinical trial NCT02326272 about?
NCT02326272 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)". The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT02326272?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 227 participants. The study started on 2014-12-15. Estimated completion is 2018-09-12.
What conditions does trial NCT02326272 study?
This clinical trial studies the following conditions: Psoriasis, Plaque Psoriasis.
What interventions are being tested in trial NCT02326272?
The interventions under investigation include: Placebo (OTHER), Certolizumab Pegol (BIOLOGICAL).
Who is sponsoring clinical trial NCT02326272?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02326272 being conducted?
This trial has 20 study locations across Arizona, California, Florida, New Hampshire, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.